15:23 , Feb 23, 2018 |  BC Week In Review  |  Company News

Merck buying oncolytic virus play Viralytics for $398M

Merck & Co. Inc. (NYSE:MRK) will acquire oncolytic immunotherapy company Viralytics Ltd. (ASX:VLA; OTCQX:VRACY) for A$1.75 per share, or A$502 million ($398 million). The price is a 182% premium to Viralytics’ close of A$0.62 on...
22:22 , Feb 21, 2018 |  BC Extra  |  Company News

Merck buying oncolytic virus play Viralytics for $398M

Merck & Co. Inc. (NYSE:MRK) will acquire oncolytic immunotherapy company Viralytics Ltd. (ASX:VLA; OTCQX:VRACY) for A$1.75 per share, or A$502 million ($398 million). The price is a 182% premium to Viralytics’ close of A$0.62 on...
16:35 , Jan 12, 2018 |  BC Week In Review  |  Financial News

Viralytics raises A$29.6M in equity placement

Immuno-oncology company Viralytics Ltd. (ASX:VLA) raised A$29.6 million ($23.16 million) through the sale of 36.1 million shares at A$0.82 ($0.64) in a placement on Jan. 5 from Lepu Medical Technology Co. Ltd. (Beijing, China). Following...
23:25 , Nov 10, 2016 |  BC Week In Review  |  Clinical News

Cavatak: Preliminary Ph Ib data

Preliminary data from 17 evaluable patients with ≥1 injectable lesion in the open-label, U.S. Phase Ib MITCI trial showed that intratumoral Cavatak plus Yervoy ipilimumab led to an ORR of 52.9%, including 3 complete responses...
23:19 , Nov 10, 2016 |  BC Week In Review  |  Clinical News

Cavatak: Preliminary Ph Ib data

Preliminary data from 8 evaluable patients with ≥1 injectable lesion in the open-label, U.S. Phase Ib CAPRA trial showed that intratumoral Cavatak plus Keytruda pembrolizumab was well tolerated with no grade ≥3 treatment-related adverse events...
08:00 , Feb 29, 2016 |  BioCentury  |  Product Development

Infectious enthusiasm

After over two decades of scant effectiveness against cancer, oncolytic viruses could be close to finding their place in immuno-oncology combination regimens, where they could both be potentiated by and improve response rates to checkpoint...
08:00 , Dec 14, 2015 |  BC Week In Review  |  Company News

Merck & Co. Inc, Viralytics deal

The companies partnered to conduct a Phase Ib trial of melanoma drug Keytruda pembrolizumab from Merck with Cavatak from Viralytics to treat patients with advanced-stage non-small cell lung cancer (NSCLC) or metastatic bladder...
07:00 , May 4, 2015 |  BC Week In Review  |  Clinical News

Cavatak: Updated Phase II data

Updated data from 57 evaluable patients with stage IIIc/IV malignant melanoma in the 2-stage, open-label, U.S. Phase II CALM trial showed that intratumoral Cavatak led to irPFS, the primary endpoint, in 22 patients at 6...
07:00 , May 4, 2015 |  BC Week In Review  |  Clinical News

Cavatak: Interim Phase I/II data

Interim data from 6 patients with advanced cancer in the open-label, dose-escalation, U.K. Phase I/II STORM trial showed that multiple doses of IV Cavatak were generally well tolerated with no treatment-related grade 2, 3 or...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Clinical News

Cavatak: Updated Phase II data

Updated data from 51 evaluable patients with stage IIIc/IV malignant melanoma in the 2-stage, open-label, U.S. Phase II CALM trial showed that intratumoral Cavatak led to irPFS, the primary endpoint, in 19 patients at 6...